Person:
Galeano Valle, Francisco

Profile Picture
First Name
Francisco
Last Name
Galeano Valle
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Medicina
Department
Medicina
Area
Medicina
Identifiers
UCM identifierScopus Author IDDialnet ID

Filters

2021 - 20224
Reset filters

Settings

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Publication
    Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry
    (MDPI, 2022-01-18) Bikdeli, Behnood; Jiménez, David; Demelo Rodríguez, Pablo; Galeano Valle, Francisco; Porras, José Antonio; Barba, Raquel; Ay, Cihan; Malý, Radovan; Braester, Andrei; Imbalzano, Egidio; Rosa, Vladimir; Lecumberri, Ramón; Siniscalchi, Carmine; Fidalgo, Ángeles; Ortiz, Salvador; Monreal, Manuel
    Background: Venous thromboembolism (VTE)—including deep vein thrombosis, pulmonary embolism, and cerebral venous sinus thrombosis (CVST)—may occur early after vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We sought to describe the site, clinical characteristics, and outcomes of VTE after vaccination against SARS-CoV-2. Methods: In a prospective study using the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) platform, patients with VTE 4–30 days after vaccination against SARS-CoV-2 (1 February 2021 through 30 April 2021) were included. VTE patients recruited from the same centers into RIETE in the same months in 2018–2019 were selected as the reference group. All-cause mortality and major bleeding were the main study outcomes. Results: As of 30 April 2020, 102 patients with post-vaccination VTEs had been identified (28 after adenovirus-based vaccination [ChAdOx1 nCov-19; AstraZeneca] and 74 after mRNA-based vaccination [mRNA-1273; Moderna, and BNT162b2; Pfizer]). Compared with 911 historical controls, patients with VTE after adenovirus-based vaccination more frequently had CVST (10.7% vs. 0.4%, p < 0.001) or thrombosis at multiple sites (17.9% vs. 1.3%, p < 0.001), more frequently had thrombocytopenia (40.7% vs. 14.7%, p < 0.001), and had higher 14-day mortality (14.3% vs. 0.7%; odds ratio [OR]: 25.1; 95% confidence interval [CI]: 6.7–94.9) and major bleeding rates (10.3% vs. 1.0%, OR: 12.03, 95% CI: 3.07–47.13). The site of thrombosis, accompanying thrombocytopenia, and 14-day mortality rates were not significantly different for patients with VTE after mRNA-based vaccination, compared with historical controls. Conclusions: Compared with historical controls, VTE after adenovirus-based vaccination against SARS-CoV-2 is accompanied by thrombocytopenia, occurs in unusual sites, and is associated with worse clinical outcomes.
  • Thumbnail Image
    Publication
    Mid-Regional Pro-Adrenomedullin, Methemoglobin and Carboxyhemoglobin as Prognosis Biomarkers in Critically Ill Patients with COVID-19: An Observational Prospective Study
    (MDPI, 2021-12-06) Oblitas, Crhistian Mario; Galeano Valle, Francisco; Ramírez Navarro, Jesús; López Cano, Jorge; Monterrubio Manrique, Ángel; García Gámiz, Mercedes; Sancho González, Milagros; Arenal López, Sara; Álvarez Sala Walther, Luis Antonio; Demelo Rodríguez, Pablo
  • Thumbnail Image
    Publication
    Predicción de mortalidad y sangrado precoces en pacientes con enfermedad tromboembólica venosa aguda mediante medición de proteína C reactiva
    (Universidad Complutense de Madrid, 2021-08-19) Galeano Valle, Francisco; Demelo Rodríguez, Pablo; Toro Cervera, Jorge del; Alvarez-Sala Walther, Luis Antonio
    Objetivos. La asociación de la medición de la proteína C reactiva (PCR) al diagnóstico y complicaciones precoces en la enfermedad tromboembólica venosa (ETV) aguda no ha sido evaluada. Nuestra hipótesis es que los niveles elevados de PCR al diagnóstico podrían estar asociados con complicaciones precoces (mortalidad, hemorragia, recurrencia) en pacientes con ETV aguda. Material y métodos. Estudio observacional prospectivo, en el que se incluyeron pacientes consecutivos con diagnóstico de ETV aguda en los que se midió la PCR en las primeras 24 horas del diagnóstico. La mortalidad, sangrado y recurrencia fueron registrados durante el seguimiento a 30 días...
  • Thumbnail Image
    Publication
    Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review
    (MPDI, 2021-03-05) Galeano Valle, Francisco; Ordieres Ortega, Lucía; Oblitas, Crhistian Mario; Toro Cervera, Jorge del; Álvarez-Sala Walther, Luis Antonio; Demelo Rodríguez, Pablo
    The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients.